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91. Introduction and background 
1.1 Diseases 
Musculoskeletal diseases (MSD) are increasingly recognised as a major and important 
group of afflictions. Rheumatic diseases, representing a substantial part among them, 
embrace a wide range of conditions, which are characterised by a distinct heterogeneity.  
Osteoarthritis (OA) is the most common rheumatic joint condition and is generally regarded 
as a degenerative disease (1). However, an inflammatory component plays an additional role 
in OA (2-5). Rheumatoid arthritis (RA) is a systemic, highly inflammatory and more severe 
disease with a lower prevalence, normally with symmetrical joint involvement (6). Both 
diseases may involve hands and feet and can be subject to differential diagnosis. 
1.1.1 Osteoarthritis 
This research project was started because the department, as part of a long-term strategy, 
wanted to focus more on OA. The research agenda in the nineties had main focus on RA, 
reactive arthritis and secondary osteoporosis and it was considered important to enhance the 
focus on other joint diseases and in particular OA. HOA was then a reasonable choice 
because quite a few of these patients had been referred to and examined at the department of 
rheumatology.  
Main signs and symptoms of OA are typically pain, stiffness and reduced physical function, 
which can influence the patients’ lives considerably. Patients with OA have barely been a 
priority for healthcare systems for a long period of time, but fortunately interest in OA has 
recently improved. Serious efforts have been made to enhance the understanding of the 
condition in terms of patho-physiological mechanisms including cartilage degradation and 
inflammation and the complex process affecting many different joint areas in the body (5;7-
10). Furthermore, work to find new pharmaceutical treatment strategies, especially disease 
modification, has been intensified, but so far no suitable disease-modifying agents are on the 
market (2;9;11-17).  
OA is oftentimes described as a booming epidemic (4) and it is a fact that both prevalence 
and incidence numbers are expanding along with the elderly populations. The overall self-
reported prevalence of OA in a Norwegian population study (age 20-80 years) was 12.8% 
(14.7% in women, 10.5% in men) (18). Prevalence studies from either Scandinavia and 
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other European countries and the United States (19-24) indicate both similar and diverging 
figures. The prevalence of knee and hip OA in Norway was 7.1% and 5.5%, respectively 
(18). Other population studies on radiographically assessed hip / knee OA both from 
Scandinavia and northern Europe have shown higher numbers (20;21;25).  
Incidence figures for Norway can be calculated from a Norwegian population survey (26) 
and the 10-year incidence for HOA is 5.6%, for hip OA 5.8% and for knee OA 7.3% (26). 
Respective figures from a Swedish study over a 5 year period are 13.6% (HOA) and 4.5% 
(knee OA) (19;20). A study from the United States from the mid-nineties found an annual 
incidence of 1%  for radiographic knee OA in women over the age of 70, HOA and hip OA 
were somewhat lower (27). Both prevalence and incidence numbers show huge 
discrepancies across studies due to heterogeneous populations and inconsistencies in the 
criteria.
Geographical variations also have an influence on the occurrence of OA. Furthermore, 
diverse risk factors do have an impact on incidence and prevalence. The most prominent 
factors for development of OA are age, female gender, genetic factors, excessive physical 
activity in either work or leisure time, overweight and other lifestyle factors (19). It is 
established that age is the strongest risk factor for OA. The high incidence of OA in 
postmenopausal women implies that hormonal factors can account for a distinct influence 
on this high occurrence (28). Genetic factors are relevant as well (29-31). There is 
increasing evidence that physically straining activities can be a risk factor, especially for 
knee OA (32;33). Important life style factors (i.e. overweight) together with expanding 
populations of the elderly can contribute to explain the rising prevalence of OA (4;34-36). 
OA can be detected in any joint in the body, but the most frequent sites are the hips, knees 
and hands. Classification criteria, diagnosis and management recommendations for all three 
forms of OA have been published (37-46). 
The strongest focus on OA is most frequently on the weight bearing joints (hip and knee) 
since it affects a majority of patients and is a prime origin for pain, disability and impaired 
health related quality of life (HRQoL) among the elderly (47). Moreover, most studies 
concerning treatment options for OA have been conducted in patients with knee or hip OA.
HOA can be regarded as an isolated, localized form of OA but is usually seen as part of a 
generalized disease (48-52).
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Therapeutic management options for OA today are multidisciplinary and complex (Figure). 
The initial and fundamental approach to treatment is information and education of patients 
and to encourage patients to perform appropriate exercises. Physiotherapy, occupational 
therapy including distribution of helping/technical devices (53-60) and support from 
nutritional therapists are also essential parts of the management program (61;62).  
Symptom modifying drugs such as traditional ”painkillers” are in the first line of the 
pharmacological treatment of the disease. Paracetamol is still the first option in most 
existing management guidelines or recommendations (22;40;41;45;46;63). The second 
alternative, if response to paracetamol is insufficient, are non-steroidal anti-inflammatory 
drugs (NSAIDs) both for oral and topical use (64;65) and the newer generation of 
cyclooxygenase 2 (COX 2) selective inhibitors. These selective COX 2 inhibitors were 
developed with the intention to minimise gastrointestinal side effects, which can be 
associated with the intake of traditional NSAIDs, especially in older rheumatic patients. 
Selective COX 2 inhibitors have been shown to increase cardiovascular risk, but subsequent 
studies have also supported that non-selective NSAIDs also increase this risk (66-68). If 
pain relief is not achieved by paracetamol and NSAIDs / COX 2 inhibitors, opoids might be 
indicated (69-71).
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In recent years symptomatic slow-acting drugs for OA (SYSADOA) like 
glucosaminoglycans (sulphate and hydrochloride) and chondroitin sulphate and combined 
glucosamine/chondroitin supplements have experienced a renaissance after being used in 
veterinary medicine for ages (72-74). They have been included in existing treatment 
recommendations (22;40;41;45;63). At the same time, the evidence is much debated and 
inconclusive (75-83). Further, also other nutritional supplements and compounds such as 
ASU= avocado soybean unsaponifiables (84) and diacerein, a natural interleukin inhibitor 
(17;85-87) have also been seen as therapeutic opportunities and have been addressed in 
several treatment recommendations (22;40;41;45;63). Nevertheless, recent 
recommendations do not include these any more, due to shrinking evidence, notably 
because of negative findings in a big, independent, placebo controlled, randomised  trial 
(75;88;89).
In active inflammatory conditions with joint effusion and/or synovitis, intra-articular steroid 
injections can be indicated (90-92). Hyaluronic acids, also administered intra-articularly, 
(93-99) have also shown modest effect in knee OA. 
Efforts to find new pharmaceutical treatment strategies have been intensified and the 
research agenda has focused on new potential treatment options targeting inflammation in 
and around the joint and possible disease-modifying OA drugs (DMOADs), unfortunately 
with no convincing results so far. Potential candidates for disease-modification are as of 
now inhibitors of pro-inflammatory cytokines like interleukins (17;100-105), tumor necrosis 
factor alpha (TNF) (106;107) and metalloproteases (MMPs) (5;17;108-110). 
In patients with advanced joint disease orthopaedic surgery and mostly joint replacement 
therapy with prostheses is widely used (22;40;41;45;63). 
1.1.2 Osteoarthritis of the hand 
HOA is a heterogeneous and common condition which characteristically affects the distal 
(DIP) and proximal inter-phalangeal joints (PIP) and the carpo-metacarpal joint of the 
thumb (CMC).  
For the most part HOA affects multiple PIP and DIP joints, but some patients present with 
isolated CMC joint involvement. The subset of erosive HOA is characterized by 
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considerable, clinical inflammation and significant and specific radiographic findings 
(erosions) (111;112).
Main symptoms of HOA are, as in all types of OA, pain, stiffness and impaired physical 
function, which can have a substantial influence on patients’ quality of life (113-117). 
Typically, HOA patients are afflicted with pain and stiffness in the hands resulting in 
problems with fine motor tasks (writing, buttoning, turn movements etc.) and activity 
limitations (57;118). Moreover, HOA patients experience loss of grip-strength and often 
involuntarily drop objects out of their hands (48;49;114;119-124). Classification criteria for 
HOA were developed a long time ago (38) and in recent years new recommendations for the 
diagnosis and management of HOA have also been developed (16;45;46;49). HOA is also a 
key manifestation for a more generalized disease and a part of the proposed classification 
criteria for generalized OA (50;52). Presence of HOA may also be a predictor for knee and 
hip OA (125).
Unfortunately, few accepted and validated HOA disease specific outcome measures exist 
compared to RA (126-129). Therapeutic approaches in HOA comprehend patient 
information and exercise, occupational therapy, orthoses and helping devices (57). 
Pharmaceutical options are mostly the same as for other types of OA, but fewer controlled 
studies have been performed (16;49;53;130). A recent trial showed effect on HOA of a 
combination of low dose prednisolone and dipyridamole (131). Surgical alternatives are 
essentially directed towards the CMC joint (5;45;132).
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Table 1: Comparison disease characteristics OA and RA 
1.1.3 Rheumatoid arthritis 
Rheumatoid arthritis (RA) is a chronic, inflammatory and symmetrical joint disease. Hands, 
knees and feet are the most frequently affected joint areas, and the wrists, MCP and PIP 
joints are the typically involved joints of the hands (Table 1). RA can develop into a severe 
systemic condition with extra-articular involvement of various internal organs. Fortunately, 
joint deformities and severe, systemic manifestations are less common nowadays (133;134) 
since new treatment modalities have provided a better and more satisfying management of 
the disease (135-139). The prevalence of RA is approximately 0.5-1% and the incidence is 
25-50 per 100 000 (6;140-142). RA is 2-3 times more prevalent in women than men 
(142;143). RA can be a differential diagnosis to HOA.  
A variety of outcome measures to monitor this condition exists within three main 
dimensions: Inflammatory activity, joint damage, HRQoL (144-152). 
Differences OA RA 
Pathogenesis mostly cartilage / moderate 
inflammation 
massive inflammation 
Joint findings Osteophytes / nodes  / 
moderate soft tissue swelling
considerable soft tissue 
swelling
Distribution of joint 
involvement (hands)
PIP / DIP / CMC MCP / PIP / wrist 
Radiographic findings Osteophytes / joint space 
narrowing
Erosions
Extraarticular disease only RA 
Laboratory findings microCRP  Elevated ESR + CRP 
positive rheumatoid factor + 
anti-CCP
Synovial fluid low leucocyte count high leucocyte count 
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Suppression of inflammation is the main objective in the treatment of RA (137), which may 
lead to prevention of radiographic progression, suppression of symptoms as pain and 
stiffness and amelioration of function. Suppression of inflammation can be achieved with 
anti-inflammatory drugs (symptom modifying) and corticosteroids (symptom and disease 
modifying) (136;137;153;154). The most commonly used disease modifying antirheumatic 
drugs (DMARDs) in the 1980s were gold salts. Methotrexate became the most widely used 
DMARD in the 1990s (155;156), either as monotherapy or in combination with 
sulphasalazine and hydroxychloroquine. Leflunomide became available in the last part of 
the 1990s.
Considerable progress in the development of new treatment strategies has brought along a 
new era of therapy for RA patients in the last decade (157). The new biological agents (e.g. 
TNF and interleukin inhibitors) (135-137) have revolutionised the management of RA and 
ameliorated the patient’s disease activity and quality of life. Importantly, access to the new 
drugs has been followed by an increasing focus on improved treatment strategies 
concentrating on early diagnosis, early use of methotrexate and tight control according to a 
treatment target and then switching of therapy, if the target is not achieved (158-162). 
1.2 Assessment of health status
Assessment of health status is important for the evaluation of the course of rheumatic 
diseases. Measurement of disease activity in RA (163;164) and HOA is advised (165) and is 
used to predict the disease course and outcome and most importantly, the effect of 
treatment. Several instruments are available to measure the burden of disease and a variety 
of patient reported outcomes (PROs) and appropriate function tests are also accessible. 
In RA, joint counts, assessment of structural damage and PROs are used to assess the course 
of the disease (163). In HOA, only few specific instruments for measurement of health 
status are available (116;126;128;165) and consensus on how to assess the condition has not 
been achieved. Nevertheless, recommendations for a core set of signs and symptoms in the 
assessment of OA including pain, function, patient global and imaging have been developed 
(166). Instruments to address these dimensions in OA are available, and are most 
comprehensively validated for weight bearing joints (167-170).  
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1.2.1 Pain 
Pain is the cardinal symptom in various rheumatic diseases, among them HOA 
(5;45;46;57;116;117;122;124;165;168), and is the signature problem for patients with RA 
(171;172). Pain is also part of the three main domains in the recommended OMERACT core 
set for assessment of OA (166) and recommended as an evaluation domain in the OARSI set 
of responder criteria for OA (173). The symptom of pain can be assessed by diverse 
outcome measures, both generic and arthritis specific. The 100 mm visual analogue scales 
(VAS) or 11-point numeric rate scales (range 0-10) are most widely used. 
1.2.2 Physical function 
Physical function is impaired as a result of the patho-physiological, inflammatory and 
degenerative processes in RA and HOA, resulting in structural changes. These structural 
abnormalities together with pain and stiffness cause disability. Impaired physical function 
has a considerable effect on RA and HOA patients' every day life 
(46;116;117;119;121;122;124;165;174;175). Disability is one of the three domains in the 
OMERACT OA core set (166) and function is a recommended evaluation domain in the 
OARSI set of responder criteria for OA (173). Hand function can also be assessed by grip 
strength and other functional performance tests (176;177). 
1.2.3 Stiffness 
Stiffness is a typical symptom associated with most rheumatic conditions such as both RA 
and HOA. It affects function and has its peak in the morning or after longer periods of 
immobilisation. Morning stiffness is commonly assessed in RA, but was not included in the 
ACR or OMERACT core sets (178-180). However, stiffness is one of the dimensions in the 
widely used PROs in OA (116;117;126;127;165;167;181;182) and has been included as a 
key proposition in the newly published EULAR recommendations for the diagnosis of HOA 
(46).
1.2.4 Health Related Quality of Life 
HRQoL is an eclectic umbrella term and sums up the impact of a disease on various 
dimensions of health in the patient’s life. Pain and physical function are essential 
constituents of HRQoL, but in addition HRQoL can be influenced by mental health, sleep 
disturbance, fatigue, social interaction, vitality and several other domains. HRQol can be 
assessed by several established PROs (183). Appropriate validated and frequently used 
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outcome measures can be generic or condition specific, multidimensional or 
monodimensional. The SF-36 is the most widely used generic, multidimensional outcome 
measure (152). Multidimensional arthritis specific instruments are the Arthritis Impact 
Measurement Scales 2 (AIMS2) (149). HOA specific instruments include the Australian 
Canadian HOA index (AUSCAN) and the score for assessment and quantification of 
chronic rheumatic affections of the hands (SACRAH) (116;117;181). The Michigan Hand 
Outcomes Questionnaire (MHQ) (184) is a generic, multidimensional outcome measure for 
the hands. Specific PROs for functional assessment of the hands are the algofunctional 
index for OA of the hand (128), the Cochin Hand Functional disability Scale (CHFS) (185) 
and the functional index for HOA (FIHOA) (129). For the rating of OA of the lower limbs 
several multidimensional, specific questionnaires are available such as the Western Ontario 
McMaster Universities OA Index (WOMAC) (167), the Hip dysfunction and Osteoarthritis 
Outcome Score (HOOS) (169), the Knee injury and Osteoarthritis Outcome Score (KOOS)
(170), the Indexes of Severity for osteoarthritis of the Hip (ISH) and Knee (ISK) (186) and 
the osteoarthritis Knee and Hip Quality Of Life (OAKHQOL) questionnaire (187). The 
Health Assessment Questionnaire (HAQ) (151) and the modified HAQ (MHAQ) (150) are 
commonly used in RA but also in other arthritidies.  
Self-efficacy is defined as individual’s estimation of their capability to plan and perform 
courses of action. The Self-efficacy scales assess coping abilities in RA patients (188).  
1.2.5 Joint counts 
Joint counts are central in the rating of disease activity in RA (147;189), but are not yet 
established as such in HOA. Joint assessment in HOA usually comprises evaluation of pain 
on palpation, soft tissue swelling / synovitis and bony enlargement (as an expression for 
osteophytes).
1.2.6 Fibromyalgia-like symptoms 
Fibromyalgia (FM) symptoms are prevalent in rheumatic diseases. (190;191). At the same 
time, the diagnosis of FM is in itself challenging (192;193) since symptoms can overlap 
with other related diseases (194). Also, the American College of Rheumatology 1990 
Criteria for the Classification of Fibromyalgia have limitations and are not recommended 
for use in the clinical setting (192;195). Yunus et al. recommended to assess FM-related 
symptoms like muscle pain, headache, concentration problems, numbness and abdominal 
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pain, since these symptoms are essential clinical manifestations (196). A recent review by 
Prodiger et al. evaluate 16 frequently employed instruments to assess FM symptoms (197). 
Thus, so far no gold standard for the diagnosis and treatment of FM exists (193), even 
though EULAR recommendations for the management of FM have been published (198). 
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2. General aim and specific research questions 
2.1 General aim 
The general aim of this thesis was to assess the burden of disease in patients with HOA 
through a comprehensive clinical examination including completion of patient-reported 
questionnaires.
2.2 Specific research questions 
 How does the Norwegian translation of the AUSCAN perform in the Oslo HOA cohort?  
     (paper I) 
 How does the AUSCAN perform compared to other arthritis specific (WOMAC, AIMS2, 
HAQ, MHAQ, self-efficacy scales) and generic (SF-36, several VAS) outcome measures 
as well as a performance based test (grip strength)? (paper I) 
 Are levels of pain, physical function and quality of life different between HOA patients, 
RA patients and healthy controls? (paper II) 
 How is the level of HRQoL in the two rheumatic diseases (HOA, RA) in comparison 
with healthy controls and population norms? (paper II) 
 Are pain levels, physical function and HRQoL different between patients with HOA and 
RA? (paper III) 
 Do HOA patients experience FM-like symptoms and how are their levels compared to 
RA patients? (paper III) 
 How is the association between joint involvement and levels of pain, physical function 
and other dimensions of health? (paper IV) 
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3. Materials and methods 
3.1 Patients and controls 
3.1.1 The Oslo Hand Osteoarthritis Cohort 
The Oslo HOA cohort was initiated in the year 2000 with the primary intention to provide 
an opportunity to evaluate the burden of disease (assessment of pain, physical function, 
stiffness, mental health and HRQoL in general) in HOA. Secondly, a cohort of HOA would 
potentially provide opportunities for studying the prediction of long term outcome. 
Patients between 50 and 70 years of age (mean age 61.6 years) with HOA were eligible to 
be enrolled in the HOA cohort, if they did not have any other rheumatic diseases. Potential 
study participants were selected by using diagnostic codes in the hospital data system. After 
a thorough review of patient records from the rheumatology outpatient department of the 
preceding two years, we identified 275 eligible patients with clinical HOA. Two hundred 
and nine (76%) individuals consented to participate in the data collection. All patients 
reported OA pain during the last month before screening. The 19 male participants of the 
cohort were not included in the analyses in articles II, III and IV. 
A total of 159 (83%) of the 190 female patients used for the analyses fulfilled the American 
College of Rheumatology (ACR) clinical classification criteria for HOA (38), whereas 31 
(16%) had clinical HOA without formally fulfilling these classification criteria. 
Radiographic OA abnormalities (Kellgren/Lawrence grade 2 or higher) in at least one of the 
finger joints were found in 176 (93%) patients (199). Seventeen (9%) and 112 (59%) 
participants also fulfilled the clinical and radiographic ACR classification criteria for hip 
OA (39) and knee OA (37), respectively. 
3.1.2 The Oslo Rheumatoid Arthritis Register (ORAR) 
The ORAR was established in 1994. Mail surveys were performed in 1994, 1996 and 2001. 
Further, a clinical examination with a comprehensive data collection was performed in 
1996-97 in individuals less than 70 years, and the respondents were re-examined 2 years 
later. These examinations had a particular focus on osteoporosis, but also on inflammatory 
activity and HRQoL.  
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Data from 194 women with RA, age between 50 and 70 years, (mean age 61.1 years) from 
the ORAR were incorporated as a comparison group in the analyses. The data from the 1998 
/ 1999 assessment were used for the comparative analyses (200). Only routinely examined 
patients from the outpatient department from the previous 2 years and patients without any 
clinical evidence of HOA were eligible for inclusion in this comparison group.  
3.1.3 Healthy controls 
The healthy control group comprised 144 female, healthy individuals (mean age 60.8 years), 
who had been randomly selected from the population register in Oslo and had undergone the 
same procedures and examinations as the RA cohort in the 1998-99 data collection 
(200;201). From the original 249 controls included in the RA study on vertebral deformities 
(201;201) we included individuals between 50 and 70 years of age according to the 
inclusion criteria for the study, but excluded individuals with clinical signs of OA or who 
reported OA as a concomitant disease.
3.1.4 Population norms 
The population data were gained from a random computer draw of the National Population 
Register among all Norwegian inhabitants between 50-70 years of age with the same digit in 
their social security number. Data from 384 female individuals (mean age 59.2 years) were 
used for this analysis (202;203). 
3.2 Data collection/logistics 
Two hundred and seventy-four individuals with HOA between 50 and 70 years of age, who 
had been examined at the outpatient rheumatology department within the previous 2 years 
were enrolled in the HOA cohort and contacted by mail. The patients who consented to 
participate received a booklet of questionnaires by mail and returned the completed booklet 
when they subsequently attended the clinical examination and other assessments according 
to the research protocol. 
The clinical examination was performed by one experienced clinician (BSC). All patients 
were interviewed by a study nurse, who also collected demographic information and 
completed the performance based grip strength test (204). All patients had radiographic 
examination of their hands (conventional radiographs) and provided a blood sample (ESR, 
used for the ACR classification criteria for the hip). The patients also had a DXA scan 
(205).
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Data from women with RA and individuals representing the general population between 
ages 50 and 70 years were already available and were used for the comparative analyses 
(200).
Table 2: PROs and function test in patient groups and controls 
OA RA Control 
Specific measures 
OA specific
     Arthritis specific
AUSCAN 
WOMAC 
AIMS2
HAQ
MHAQ
Self- efficacy scales 
X
X
X
X
X
X
X
X
X
X
Generic measures SF 36 
SF-6D
VAS
(pain, fatigue, global and 
fibromyalgia like 
symptoms) 
X
X
X
X
X
X
X
X
X
(pain and fatigue)
Performance based 
measure
Grip strength X X 
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Table 3: Data reported in the individual papers 
Paper I Paper II Paper III Paper IV 
Demographics      
Age X X X X 
Gender X females females females 
Disease
duration
X        X X  
Education  X   
Co-morbidity  X   
Outcome measures      
SF-36 X X X X 
SF-6D  X   
AIMS2 X  X X 
HAQ   X X 
MHAQ X  X  
AUSCAN X   X 
WOMAC X    
VAS pain X X X X 
VAS fatigue  X X  
VAS global   X  
VAS
(fibromyalgia 
like symptoms)
  X  
Self efficacy 
scales
  X  
Grip strength  X X X 
Joint counts    X 
Radiology      
Hand x-rays X X   
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3.3 Patient-reported outcome measures 
3.3.1 OA-specific measures  
AUSCAN 
The Australian Canadian HOA Index is a disease-specific health status measure developed 
for HOA, which addresses pain (5 items), stiffness (1 item) and difficulties with daily 
activities (9 items) during the last 48 hours (127). We used the Likert scale version, which 
gives the patient a choice of five response options (none, mild, moderate, severe, extreme 
(0-4)) within each of the 15 items. The pain dimension measures the amount of hand pain at 
rest, when gripping, lifting, turning or squeezing objects. The stiffness dimension asks for 
stiffness after wakening. The physical dimension is capturing difficulties with the following 
tasks: turning taps and a round doorknob or handle, doing buttons, fastening jewellery, 
opening a new jar, carrying a full pot with one hand, peeling vegetables/fruits, picking up 
large, heavy objects and wringing out washcloths. 
Subscale scores were calculated by simple summation of the assigned values scored on 
component items and we presented normalised data with a score range of 0-10. The 
translation procedures followed standardised, international guidelines (206). Professor 
Nicholas Bellamy gave permission to use the AUSCAN free of charge for this non-
commercial research project.  
WOMAC
Western Ontario McMaster Universities Osteoarthritis Index is a widely used, self-
administered, specific outcome measure for hip and knee OA. It is a multidimensional self-
administered measure which captures pain, stiffness and physical functional disability (167). 
The questionnaire contains 5 questions on pain, two on stiffness and 17 different questions 
on physical function. Scores are calculated in the same manner as the AUSCAN scores. The 
WOMAC was as the AUSCAN employed by courtesy of professor Bellamy.  
3.3.2 Arthritis specific measures  
AIMS2
The Arthritis Impact Measurement Scales 2 (AIMS2) is a multidimensional instrument 
which was initially developed for RA, but can also be used in other rheumatic arthritidies 
such as OA. It captures several relevant domains of health and has been widely used by our 
research group, especially in the data collection for the ORAR. The questionnaire has 12 
25
scales (one of them with a focus on hand and finger function). The scales can be merged 
into five main components: physical, mental, social, pain, and work. Each scale is graded 
from 0 to 10 (10 representing the poorest health) (149). 
HAQ
The Health Assessment Questionnaire measures self-reported physical function in RA and is 
also applied in other rheumatic diseases (151). It consists of 20 questions on eight categories 
of relevant physical functions: dressing and grooming, arising, eating, walking, hygiene, 
reach, grip, and common daily activities. The highest score for any question in each of the 
eight categories is selected to represent that respective category. The scores in each category 
range from 0 (without any difficulty) to 3 (unable to do) and the score is upgraded to the 
level of 2, if the patient reports use of helping devices and /or receives assistance within the 
same category. The mean score of the eight categories is calculated (range 0-3, 3 = worst) 
and presented as the HAQ score. 
MHAQ
The Modified Health Assessment Questionnaire is a modified version of the original HAQ. 
Each of the eight items represents one of the eight categories of the HAQ. A mean MHAQ 
score is computed from all eight items, with a range from 1 to 4, with 4 representing the 
worst level of functioning (150). 
Self-efficacy 
The Self-efficacy Scales measures the perceived ability to influence rheumatic pain (five 
items), physical function (nine items), and symptoms (six items). The scale ranges from 10 
(very uncertain) to 100 (very certain) (188). 
3.3.3 Generic measures
SF-36
The Short Form-36 is the most commonly utilized generic, multidimensional health status 
questionnaire, measuring 8 dimensions of health: physical function (10 items), role 
limitations due to physical health problems (4 items), bodily pain (2 items), general health 
(5 items), vitality / energy (4 items), role limitations due to emotional problems (3 items), 
and mental health (5 items). SF-36 scores range from 0 to 100, with low scores indicating 
poor health (152). 
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SF-6D
The Short Form-6D is a preference-based utility instrument based on data from the SF-36, 
which are converted to a utility score. The score is based on 6 dimensions of health 
(physical functioning, role limitations, social functioning, pain, mental health, and vitality), 
each with 4–6 levels. The score range is from 0.29 to 1.0, with 1.0 reflecting  
perfect health (207;208). 
Visual analogue scales (VAS) 
Visual analogue scales (0 -100 mm) were used for joint pain, fatigue and patient global 
assessment (general OA disease activity) in this thesis, with no and intolerable pain / fatigue 
/ disease activity as the anchoring points. The exact Norwegian expression we used for the 
VAS global was: Spørsmål om sykdomsaktivitet  ” Vi ber deg vennligst vurdere aktiviteten 
i artrosesykdommen i løpet av den siste uken. Når du tar alle symptomer med i betraktning, 
hvordan synes du tilstanden er? ” The respective English translation is as follows: Question 
about disease activity “ We ask you kindly to assess the osteoarthritis disease activity during 
the past week. Taking all symptoms into account, how is your condition? ” 
Perceived intensity of FM-like symptoms was also explored by VAS. The following 
symptoms were examined: abdominal pain, headache, numbness in fingers, muscle pain / 
muscular tenderness, and concentration problems, with anchors being no symptoms / 
intolerable symptoms. 
3.4 Physical examination and other assessments 
3.4.1 Joint counts and clinical examination 
All joint assessments were performed by the same clinician (BSC). The CMC, MCP, PIP 
and DIP joints were examined for 4 categories of abnormalities and corresponding joint 
counts were computed: tenderness / pain on motion (tender joint count (TJC)), soft tissue 
swelling (swollen joint count (SJC)), bony enlargement (hard tissue swelling, including 
Heberden and Bouchard nodes) (bony enlargement joint count (BEJC)) and limited 
motion, defined to be less than “normal“ range of motion (limited motion joint count 
(LMJC)). Absence or presence of abnormal findings in individual joints was scored as 0 and 
1, respectively. 
For each of the 4 categories of clinical abnormalities, we computed several different 
combinations of joint counts: DIP joints (range 0-8), PIP joints (range 0-10) including the 
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first interphalangeal joint (IP-1), CMC joints (range 0-2), DIP+PIP joints (range 0-18) and 
DIP + PIP + CMC joints (range 0-20). 
3.4.2 Performance based measure
Grip strength 
Grip strength (kg) was assessed in all patients (HOA, RA) and healthy controls with the 
Jamar hand dynamometer (Jamar, Clifton, NJ). The best performance of 2 attempts was 
recorded (204;209). 
3.4.3 X- rays  
Traditional x-rays of the hands in AP view were taken from all patients. The x-rays were 
graded according to the Kellgren and Lawrence scale (199), which is the most widely used 
scoring system for radiographic assessment of OA and was developed as early as 1957. The 
K&L score is used in both epidemiological and clinical studies due to a long tradition and 
high feasibility. It is a global score assessing the DIP, PIP, IP, MCP and CMC-1 joints on a 
0-4 scale based on the presence and size of osteophytes, joint space narrowing, sclerosis, 
cysts and altered shape of bony ends: 0 = no OA, 1 = doubtful OA, 2 = definite minimal 
OA, 3 = moderate OA, 4 = severe OA. Epidemiological studies often use K&L grade > 2 as 
an osteoarthritis definition. 
3.4.4 Demographic variables 
Demographic variables were obtained from the questionnaires and the patient interviews.
The patients provided some information by filling out the questionnaires beforehand and 
gave additional information during the interview with the study nurse, who recorded 
duration of education, time from onset of disease (disease duration), concomitant 
medication and co-morbidities.  
3.4.5 Blood samples 
A blood sample was drawn from all patients. The ESR was used for the assessment of the 
ACR criteria for the hips (37). 
3.5 Statistics 
The statistical analyses were performed by Statistical Package for Social Sciences (SPSS, 
SPSS Inc, Chicago, Illinois) (version 10.1- paper I, version 12.0 - paper II, version 14.0 – 
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paper III and paper IV) and Statistical Analysis Software (SAS, Institute, Cary, NC)  version 
9.1.3 (paper III). P-values equal to or below 0.05 were regarded as significant. Statistical advice 
and help with statistical analyses with the SAS was given by one of the co-authors (PM).
3.5.1 Descriptive statistics 
For descriptive statistics mean was used as index of location and SD as index of dispersion 
for continuous variables, whereas number of cases (N) and percentages were used for 
categorical variables. Cronbach alfa was used to explore the internal consistency (paper I).
3.5.2 Bivariate analyses 
Two sample t-test was used for comparisons of two groups (paper I and IV), whereas one-
way Analysis of Variance (ANOVA) was used for multiple group comparisons (paper II and 
III). Correlations were reported with Pearson correlation coefficient (paper I and IV). 
Two sample t-test in paper I was applied to examine the discriminatory abilities of health 
status measures (AUSCAN, WOMAC, AIMS2, SF-36 and MHAQ) across different 
subgroups of patients (HOA patients in two different age groups, fulfilling / not fulfilling 
the ACR classification criteria, presence/absence of radiographic abnormalities and female / 
male gender). In order to compare the level of discriminatory abilities, differences were 
standardised (difference divided by the standard deviation of the difference). 
In paper IV two-sample t-test was used to compare health status between patients with and 
without joint involvement in specific joints areas.  
One way analysis of Variance (ANOVA) was used in papers II and III to assess the 
difference between groups .This test is equivalent to the independent sample’s t-test. 
In case of more than two groups we used Tukey’s post hoc test for pairwise group 
comparisons. 
S scores in paper II were calculated for the purpose of detecting the disparity in HRQoL 
between patient groups versus a control group and the general population and were 
calculated by subtracting the mean scores of each of the 8 SF-36 scales for the patient 
groups and the control group from the mean values of population norm values. These 
differences were divided by the standard deviation of the general population values for each 
score. This approach was also chosen in a previous paper from our research group on 
ankylosing spondylitis (202).
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3.5.3 Multivariate analyses 
Analysis of Covariance (ANCOVA) was employed for group comparisons of continuous 
variables in papers II and III with adjustment for, age, number of co-morbidities and years 
of education. Tukey’s Post Hoc test for pairwise group comparisons was subsequently 
applied in paper II. Simes’ procedure was applied for correction of multiple comparisons. 
This procedure was chosen over the more known, but conservative and low-powered 
Bonferroni correction. 
3.6 Legal and ethical aspects 
The study was conducted according to the ethical principles of the Declaration of Helsinki. 
All participating patients had given written informed consent before entering the study. The 
study was approved by the regional ethical committee, and the storage of data was approved 
by the Data Inspectorate.  
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4. Summaries of results 
4.1 Paper I 
Performance of the Norwegian version of AUSCAN - a disease-specific 
measure of hand osteoarthritis 
The paper focused on the examination of the performance of the Norwegian version of the 
AUSCAN Index as a disease-specific health status measure in patients with HOA. As a first 
step we translated the English version of this questionnaire to Norwegian according to   
standardised guidelines. One hundred and ninety-nine patients with clinical HOA from the 
Oslo HOA cohort had undergone a comprehensive clinical examination including grip 
strength and completed several self-reported health status questionnaires. The AUSCAN 
HOA index captures three different dimensions of hand OA: pain (5 items), stiffness (1 
item), and difficulties with daily activities (9 items). Our pre-study hypothesis was to 
identify AUSCAN as a specific hand measure with strong correlations to hand measures and 
lower correlations to other general measures of musculoskeletal health. The applied 
statistical methods were Pearson correlation coefficients, two sample t-test in order to 
demonstrate the discriminatory abilities of health status measures across different subgroups 
of patients and calculation of standardised differences (difference divided by SD of the 
difference) to compare the level of discriminatory abilities. The internal consistency of the 
AUSCAN regarding pain and function was excellent. The AUSCAN pain and physical 
scores correlated substantially to each other and moderately to the stiffness scale. The 
AUSCAN physical scale correlated moderately to substantially to other measures within the 
same dimension, the highest correlation being seen with the AIMS2 hand and finger 
function scale (r = 0.73). The standardised differences between patients with and without 
radiographic abnormalities were numerically larger for the AUSCAN pain and physical 
scales than for other measures. In conclusion, the Norwegian version of the AUSCAN 
appeared to have an acceptable clinimetric performance and is a suitable tool for assessment 
of HOA. 
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4.2 Paper II 
Health-related quality of life in women with symptomatic Hand 
osteoarthritis: a comparison with rheumatoid arthritis patients, healthy 
controls, and normative data 
Data on the burden of disease in HOA are limited, and the main objective of this study was 
to highlight HRQoL in patients with HOA by comparison with RA patients, healthy 
controls, and normative data from the general population,. The comparison groups 
comprised 190 HOA and 194 RA patients, 144 healthy women and 384 population norms, 
all females within the same age range of 50-70 years. Health status was assessed by the 
following patient reported outcome measures: the SF-36, SF-6D, MHAQ, pain and fatigue 
VAS. Grip strength was also measured. Scores were compared by ANOVA and the by 
ANCOVA, adjusting for age, number of co-morbidities and years of education. Further, the 
disparity between patients and population subjects was measured by calculation of S scores 
for the SF-36. 
HOA and RA patients demonstrated worse scores on all assessed dimensions of health 
compared with healthy controls. RA patients had the most impaired general health (SF-36), 
poorest physical function (MHAQ, SF-36 physical, grip strength), and the worst level of 
fatigue compared with HOA patients. HOA patients showed worse mental health (SF-36). 
Mean utility scores (SF-6D) in HOA and RA were 0.64 and 0.63, respectively, with a mean 
difference compared with healthy controls of 0.13 in HOA and 0.14 in RA patients. A clear 
difference between individuals with a rheumatic diagnosis (HOA, RA) and population 
subjects was shown through the S scores, which demonstrated a clear gap between patients 
and controls. The S scores between healthy controls and the general population were 0, 
implying that the control group was representative for the general population.
This paper demonstrates that HOA patients have a similar overall burden of disease 
compared to female RA patients and experience a considerable impact on HRQoL in 
comparison with healthy controls. 
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4.3 Paper III 
Health status and perception of pain: a comparative study between 
female patients with hand osteoarthritis and rheumatoid arthritis 
The aim of this study was to emphasise the burden of disease, evaluated by measures of pain 
and HRQoL between two groups of rheumatic diseases: female patients with HOA and RA. 
One hundred and ninety female HOA patients were compared to 194 female RA patients of 
the same age. We assessed HRQoL with the same instruments as in paper II and in addition 
the following questionnaires: AIMS2, HAQ and self-efficacy scales. We further compared 
levels of fibromyalgia (FM) - like symptoms (headache, muscle pain, numbness, and 
concentration problems). We used multivariate ANCOVA to adjust for age, number of co-
morbidities and years of education. Sime’s procedure was used to adjust for multiple testing. 
Our findings pointed out that RA patients present a marked impairment of physical function 
compared to HOA patients. Pain, on the other hand, was numerically worse in two out of the 
three pain measures (SF-36 and VAS pain) and statistically worse in the AIMS2 in HOA. At 
the same time, the HOA group also had worse scores for FM-like symptoms. In conclusion, 
physical health was reported to be worse in RA, pain intensity on the other hand, was worse 
in HOA.
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4.4 Paper IV 
Distribution of joint involvement in women with hand osteoarthritis and
associations between joint counts and patient-reported outcome measures 
In this paper we explored the association between clinically assessed finger joint 
involvement (joint counts) and patient outcome measures in HOA. The study population 
consisted of 190 female patients from the Oslo HOA cohort.  All participants had completed 
a comprehensive clinical examination with evaluation of tenderness / pain, soft tissue 
swelling, bony enlargement and limited motion in the DIP, PIP, MCP and CMC joints. 
Furthermore, grip strength had been measured and the patients had completed several 
patient reported outcome questionnaires (AUSCAN, AIMS2, HAQ, SF-36, VAS pain). 
Statistical methods were independent samples t-test and Pearson correlation coefficients. 
DIP joints were predominantly affected in HOA. Joint tenderness / pain was a major 
indicator of impairment of health status and presence of tenderness / pain in any PIP or DIP 
finger joint was associated with worse health status. Also the three remaining joint 
assessments were in general linked to poorer health status, but associations were mainly not 
statistically significant. Correlations between tender and swollen joint counts in most finger 
joint areas and scores of hand specific outcome measures (AUSCAN, AIMS2 hand + 
finger), VAS pain and grip strength were weak to moderate. As expected, associations 
between joint counts and scores of general pain, physical function and other dimensions of 
health (AIMS2 and SF 36) were low. In summary, our findings indicated that tenderness / 
pain joint counts (CMC, PIP and DIP) in HOA correlate moderately to worse scores for key 
dimensions of health.
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5. General discussion 
The primary purpose of this thesis was to bring the burden of disease for patients with HOA 
into focus and to describe and highlight main symptoms such as pain, stiffness, limited 
function and other relevant aspects of HOA. In the following, the strength and weaknesses 
of the applied methods will be discussed followed by a discussion of the main results. 
5.1 Methodological aspects 
5.1.1 HOA patients 
The Oslo HOA cohort was established in 2000 with the motivation to assess and outline the 
burden of disease in HOA. Most data from HOA cohorts are based on information from 
large, often community surveys (20;26;47;48;114;115;121;210-218) with substantial 
numbers of patients and often only self reported data. Few studies on HOA have attained 
patients from a clinic and or outpatient department as we have done 
(116;117;122;124;181;182). Since the threshold for receiving patients in our clinic is low, 
we were able to recruit patients for this study from our outpatient unit. This HOA cohort is 
therefore composed differently compared to for example the Norwegian population study 
from Ullensaker (18) or other population based studies. Hence, the Oslo HOA patients 
represent a preselected group with a more distinct disease and it is likely that the 
characteristics of the cohort are different from the general HOA population. This difference 
limits the external validity and caution should be applied in the interpretation of the results 
on a population level. Thus, population based study findings might represent the underlying 
general population to a greater extent than the hospital-based Oslo HOA cohort. However, 
in the Oslo HOA study we were able to conduct a very comprehensive data collection with a 
joint examination of the patients. A similar detailed assessment of the condition would be 
difficult to perform in a large population study.  
Further, a significant part of the patients in the Oslo HOA cohort had a more generalised 
condition. As many as 60% of the cohort (female participants) had also clinical knee OA 
and 9 % hip OA, according the respective ACR classification criteria (37-39). Simultaneous 
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occurrence of OA in different joint areas has also been observed in other studies 
(50;51;212;219;220).
No gold standard for the diagnosis of HOA has been developed so far, but the newly 
published EULAR recommendations for the diagnosis of HOA (46) suggest 10 clinically 
oriented key propositions, a result of scientific evidence and expert opinion, which should 
be taken into consideration for the diagnosis of HOA (table 4). This publication 
recommends the consideration of a composite of several key features of HOA including risk 
factors, clinical manifestations, differential diagnosis, imaging and laboratory assessments 
for the achievement of the diagnosis of HOA. The main differences between the ACR 
classification criteria and the EULAR recommendations is that the first was generated for a 
research setting, whereas the EULAR recommendations emphasise a clinical diagnosis.
The inclusion criteria for the Oslo HOA study were predominantly chosen on the grounds of 
typical clinical features of HOA, at a time when the EULAR recommendations were not yet 
developed. We therefore used the available ACR classification criteria in order to describe 
our cohort. This approach has also been used by others for hospital based studies on HOA 
(116;117;122;124;181;182).
One of the 10 propositions in the EULAR paper refers to subsets of HOA i.e. IP (inter-
phalangeal) OA, thumb base OA or erosive OA, which seem to have different risk factors 
(221;222) and can lead to different outcomes (111;122;124;124;223). In retrospect, it might 
have been an advantage to distinguish between these three subsets in our study.
To our knowledge, so far only few other publications refer to studies where patients were 
recruited similarly to our approach and with a comparable number of patients 
(116;117;124;181;182). In the studies from Austria patients were selected from an 
outpatient clinic in order to assess pain, function and stiffness in rheumatic hands by using 
the SACRAH (116;117;181;182). In a French study patients were recruited from two 
rheumatology and rehabilitation departments with the intention to explore disability and 
pain induced by IP and thumb base HOA (124). Both studies had similarities with the Oslo 
HOA cohort with regard to patient enrolment and achieved similar results regarding 
impaired function and pain in HOA.  
The Genetics, Arthrosis and Progression (GARP) study from the Netherlands investigated 
the course of HOA over two years by using the self-reported outcome measure AUSCAN, 
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and by performing joint examination (lateral pressure on IP and CMC joints) and 
radiographs (224). The results showed worsening of pain and function and radiographic 
progression.
It is known that OA / HOA is more common in women than in men (18;27;216;225;226), 
but the female / male ratio in our study was higher than seen in most populations surveys on 
HOA but a few papers which are hospital based refer to comparable ratios 
(116;117;124;181;182;224). We were unable to find a good explanation for the high female 
/ male ratio besides the fact that hospital referred patients may be preselected and that HOA 
might be more severe in females than in males. After consulting with our statistical 
collaborator, we decided not to include the men in the analyses for papers II-IV, since the 
number of men was too small. Moreover, the healthy control group, which was to our 
disposition comprised women only and we did not have access to similar data from an 
existing cohort of healthy men.  
Another proposition from the EULAR paper focuses on the importance of the differential 
diagnosis. We excluded patients with signs and symptoms of other arthritidies from 
inclusion in the cohort and also conducted assessment of laboratory tests and radiographs of 
the hands, which is advised in the EULAR recommendations. 
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Table 4: 10 key propositions EULAR recommendations for the diagnosis of HOA 
1 Risk factors: sex, age, menopause, family history, obesity, high BMD, forearm muscle 
strength, joint laxity, usage 
2 Typical symptoms: pain, stiffness 
3 Clinical hallmarks (Heberden+ Bouchard nodes, deformities) 
4 Functional impairment 
5 Polyarticular HOA/ increased risk development of OA at other sites 
6 Subsets with different risk factors and outcomes 
7 Erosive HOA 
8 Wide differential diagnosis (PSA, RA) 
9 Gold standard: plain radiographs (JSN, osteophytes,sclerosis) 
10 Blood tests (not needed for diagnosis, but for differential diagnosis) 
EULAR evidence-based recommendations for the diagnosis of hand osteoarthritis: report of 
a task force of ESCISIT (46).
5.1.2 RA patients 
The rationale for the use of RA patients as a reference population and control group was that 
RA patients usually show substantial symptomatology connected to the hands and that RA 
is a differential diagnosis to HOA (46). Even more importantly, RA is generally appraised 
as a severe rheumatic disease by patients, health care providers, decision makers and regular 
people. Previous studies had shown that impairment of function in OA might attain the same 
disability level as in RA (116;117;124;185;227;228).
A strength of this comparison was that the RA patients were recruited from a well studied 
cohort in the ORAR register and that both the RA and HOA patients had been examined in 
the outpatient clinic during the 2 years preceding their assessment for this study. The 
assessment of the RA patients had been performed in the same department and the RA 
patients had answered many of the same outcome questionnaires and performed the same 
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performance based test (grip strength) as the HOA patients. The ORAR is presumed to be 
representative for the general RA population in Oslo and is 85% complete for the age group 
of 20-79 years (6;229). RA is generally considered a severe and disabling disease, in 
contrast to HOA, which is often regarded as a more benign “wear and tear” arthritis 
condition. Our hypothesis based on clinical experience was that patients with HOA might 
have a similar overall burden of disease as patients with RA.
5.1.3 Controls and population norms 
Control groups are widely used to position research data and to demonstrate how patient 
groups might differ from the underlying population. Similar utilisation of controls has also 
been applied in earlier studies from our group across different rheumatic conditions such as 
systemic lupus erythematosus (SLE), ankylosing spondylitis (AS) and RA (200-202;230-
232;232;233) and has also been used in another HOA study (116)  Data from the control 
group used in this HOA study were originally collected in a study on vertebral deformities 
in female RA patients, i.e. the data from both RA patients and controls were from the same 
comparative study. Therefore, we assumed that these controls might constitute a suitable 
control population also for the HOA patients (200;201;232). The controls were defined as 
“healthy” since individuals with concomitant OA or clinical signs of OA were excluded.
A particular strength was that we were able to use two different control groups as reference 
populations regarding the SF-36 data. One group comprised the individuals from the RA 
study (200;201) and in addition population norms for SF-36 were used for comparison. The 
population norms were gained from a random computer draw from the National Register of 
Norway (203). We had no access to the data on concomitant diseases in this sample. As a 
consequence this population group was not screened for rheumatic diseases for example 
OA, which can be regarded as a limitation. However, HRQoL measures were similar in the 
controls and population norms. 
5.1.4 Outcome measures, instruments and clinical examination 
When we started our HOA project, we had the idea to include similar dimensions of 
assessment which are widely used in outcome research in RA. Thus, we wanted to perform 
a comprehensive data collection including PRO’s, a functional performance test, imaging 
and joint assessment. We further considered the recommendations of outcome measures 
from the OMERACT conference in 1996 (166). Moreover, in a later published opinion 
paper Kloppenburg et al. (165) underline that future research in HOA should explore 
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outcomes, including components of disease activity, function and damage, which supports 
our approach to assess HOA. 
Measurement of HRQol in HOA was the main objective in our study and included 
assessment of signal symptoms like pain/function and other relevant components of HRQoL 
through a variety of instruments / PROs. It is important to utilize measures mirroring key 
signs and symptoms of OA according to the OMERACT core set (166). Also other and 
newer publications like the EULAR recommendations for the diagnosis of HOA (46) and 
the paper from Kloppenburg et al (165) emphasise the importance of main symptoms in the 
assessment of HOA. Symptoms in HOA were measured by the disease specific AUSCAN 
(HOA) and WOMAC (knee and hip OA). The AUSCAN is a widely used self-reported 
HOA measure and has also been applied in the data collection in other HOA cohorts 
(113;123;182). Both AUSCAN and WOMAC measure pain, stiffness and function. Ideally, 
one could have included other specific measures like the SACRAH (116;117), the Cochin 
functional index (185;228) or the FIHOA (129). Unfortunately, the only other 
multidimensional specific questionnaire SACRAH was not published and available for us at 
the time of our data collection and we did not have access to specific functional outcome 
measures like the FIHOA at that time point. The MHQ is a non OA specific measure which 
also could have been included since it focuses on hand function and has been used for HOA 
in other studies (114). However, our patients were already presented with a comprehensive 
booklet of outcome measures and we did not want to appear too demanding. 
Other arthritis specific questionnaires we used included AIMS2, HAQ and MHAQ, which 
made our data collection quite extensive. AIMS2 was included mainly because it comprises 
scales with a specific focus on upper extremity function whereas the scores of MHAQ/ 
HAQ as well as the SF-36 physical functioning scale are more strongly influenced by lower 
extremity function. Further, we also had access to AIMS2 data in the comparative RA 
control group. The MHAQ should be scored in the same way as the original HAQ with a 
range from 0-3. Historically, in Norway the MHAQ has been scored on a scale from 1- 4 as 
originally suggested by Ted Pincus. His idea was to use the same qualifiers as were used in 
the Steinbrocker functional classification (234). However, we are now changing to a score 
from 0-3 which makes it consistent with the HAQ score. The widely used generic SF-36 is 
another important instrument commonly used to outline health status and allows comparison 
of HRQoL across different diseases and with healthy individuals. We further calculated the 
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utility measure SF-6D. Preferably, we might have appended other additional utility 
measures, for example, the EQ-5D or 15D (208;235). There exists no standardised utility 
measure so far and we chose to restrict the data collection to one accepted utility instrument 
with the intention to spare our patients the burden of too many questionnaires. 
Psychological and sociological factors can affect outcome in chronic rheumatic disease 
(236). The arthritis self-efficacy scales reflect the patient’s perceived capability to cope with 
their pain, physical function and symptoms of rheumatic diseases. Self-efficacy data were 
also available from the RA control cohort, which gave us the opportunity to also compare 
self-efficacy levels between HOA and RA. 
The idea to include FM-like symptoms was based on the awareness that secondary 
fibromyalgia is frequent in RA and other rheumatic diseases (190;191) and these symptoms 
were assessed also in the ORAR data collection. To our knowledge these symptoms had not 
been examined in HOA before. A gold standard for the diagnosis of FM is not yet 
established (192), but Yunus et al. have suggested assessment of FM-like symptoms on 
VAS earlier (196).
The sole performance based test in our data collection was grip strength. We chose this 
approach since it is a well-established instrument and the control RA group had performed 
the same assessment. Ideally, one might have added other performance based tests such as 
the Moberg pickup test (176) or the Arthritis hand function test (177), but again we had to 
restrict the number of included instruments in the examinations due to feasibility reasons. 
Joint counts are part of the composite disease activity score (DAS) in RA (147;189). We 
employed joint counts in our assessment of HOA and contemplated that joint assessments 
could be part of a future composite score in HOA, as suggested in a recent publication 
(237). The EULAR recommendations for the diagnosis of HOA focus on the importance of 
typical symptoms such as pain and stiffness as well as functional impairment in the 
assessment of HOA (46). Another recent publication on the research agenda for HOA 
recommends measurement of pain, function, stiffness for HOA as well (165). We did not 
include the assessment of aesthetic damage in our data collection, since we were not aware 
of the importance of this issue for patients at the time of the data collection, nearly 10 years 
ago. Newer publications have emphasised that aesthetic damage is a concern for patients 
with rheumatic diseases (114;238). In retrospect, we should have included an accordant 
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instrument like the MHQ to give the patients the opportunity to express this important 
dimension.  
Radiographic examination was performed, but assessment of radiographic joint 
abnormalities was not part of the current research questions and has not been performed 
until recently (239-242). 
5.1.5 Statistical methods  
We used parametric statistical methods such as t-test, ANOVA/ ANCOVA and Pearson 
correlation coefficients in the analyses for this thesis because the distributions of the 
residuals were close to normal. Comparisons between patient groups and healthy controls 
were performed on a group level using independent samples t-tests. Initially, we used 
matched paired analyses, which we thought were the most appropriate tests for case/control 
studies. After consultation with our statistician, though, we altered our approach to group-
wise comparisons, because our design was only matched on age and gender and in this case 
it is more appropriate to do the analyses on a two-sample group level with adjustments for 
relevant confounding factors. 
We performed one-way ANOVA in parts of the analyses, even though we had two groups 
only. However, for a two-group comparison, the ANOVA F-test is equivalent to the more 
known independent sample t-test. 
We used a radar chart, also referred to as spider diagram, which recently has been 
highlighted as an effective way of presenting data on general health (i.e. SF-36 data) (243).
5.2 Main results 
5.2.1 Clinimetric properties of the Norwegian AUSCAN
The AUSCAN is a widely used multidimensional HOA specific patient-reported outcome 
measure and was at the time of our data collection the only accessible specific questionnaire 
for HOA. Bellamy et al. have shown that the instrument is reliable, valid and responsive in 
the original English version (127) and the AUSCAN has been described as a robust outcome 
measure for HOA in a review article (244). The Canadian GOGO study and a community 
based survey from England supported that the AUSCAN has good construct validity and is 
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reliable (242;245;246). Moreover, the GOGO study demonstrated that the AUSCAN can 
measure change over time (247). The AUSCAN has been translated into numerous 
languages, as well, and performs suitably after translation and cultural adaptation. Few of 
these studies have been published, but are referred to in the AUSCAN manual.  
Our study on the clinimetric performance of the AUSCAN included numerous other 
instruments for comparison. The Norwegian version of the AUSCAN showed good internal 
consistency within the scales as also previously demonstrated for the original version and 
other translations. We found substantial correlations between the AUSCAN pain and 
physical dimension of a magnitude which was consistent with the association between other 
pain and physical dimensions in the current study and pain and physical scales in RA (248).
As expected, AUSCAN pain correlated moderately (with values between 0.48-0.64) to other 
pain measures, and correlations were weaker to other dimensions. A strength was that we 
were able to study correlations to three different measures (VAS, AIMS2 and bodily pain in 
SF-36). The strongest association was observed with AIMS2 pain, the weakest was as 
expected to SF-36 which captures a wider and more general pain construct than AUSCAN 
pain.
Correlation of AUSCAN physical could be studied for numerous physical measures and 
scales. The strongest correlation was with AIMS2 hand and finger which supports that both 
these instruments measure the same construct. Correlations to HAQ and SF-36 physical 
were as expected weaker since these instruments have a rather strong focus on lower 
extremity function.  
An important feature is to which extent an instrument is able to discriminate between 
subgroups of patients, based on demographic and disease characteristics. In our study 
patients reported worse health with increasing age. Females, in general, reported worse 
health than men. Further, the AUSCAN discriminated more than other instruments between 
patients fulfilling and not fulfilling the ACR classification criteria for HOA and having 
versus not having radiographic OA findings. These observations support that the AUSCAN 
is more specific for HOA features than the other included instruments.  
In summary, the AUSCAN integrates core measures of HOA like pain, function and 
stiffness and our results support its performance as a HOA specific multidimensional 
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outcome measure also in the Norwegian translation with satisfactory levels of validity and 
discrimination between relevant subgroups of patients (126;127).
We have at a later time point also used the Norwegian translation of the AUSCAN in an 
intervention study with CrX-102 versus placebo in patients with HOA (131). This dataset 
was also used to further explore responsiveness of the AUSCAN (237). The results also 
supported that AUSCAN is responsive to changes in health status in HOA. Thus, AUSCAN 
is appropriate for use in clinical trials.  
5.2.2 Comparison of HRQoL between patients and controls  
Gabriel et al. showed in an elegant study that the disease specific indirect and nonmedical 
costs for OA are considerable and approach those for RA compared to controls (249). Since 
OA has a very high occurrence the disease has a substantial impact on society from a health-
economic point of view.  
The research group at Diakonhjemmet hospital has earlier compared HRQoL in patients 
with other rheumatic conditions (SLE, AS and RA) to controls (202;233). Dagfinrud et al. 
demonstrated that AS inflicts all main dimensions of health (202) and Uhlig et al. showed 
that RA imposes a considerable burden of disease across all age groups in both women and 
men (233). The burden of disease in rheumatic conditions can be assessed by a variety of 
questionnaires as has been outlined in previous chapters of this thesis.
When we sought to illustrate HRQoL in HOA in comparison to healthy controls the SF-36 
along with VAS scales seemed to be the appropriate choice of instruments. Patients with 
HOA and RA had statistically worse crude scores for all dimensions of health (SF-36) in 
comparison to healthy controls in our study. The adjusted average difference in utility (SF-
6D) between healthy controls and patients with HOA and RA was 0.13 and 0.14 which 
suggests that HRQoL is decreased by 13 quality adjusted life years (QALYs) in 100 HOA 
patients compared to healthy controls. The overall differences between healthy individuals 
and patients, either with HOA or RA, were of a similar magnitude. We chose to illustrate 
the distinct disparity between the two rheumatic diseases and the controls by showing the 
crude SF-36 values in a spider diagram and by S scores. This graphic presentation gives a 
visual illustration of the gap between healthy and diseased individuals. The spider diagrams 
can also be used to illustrate longitudinal changes (243). It was expected to find a difference 
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between the diseased and the healthy groups of individuals. Even so, it was somehow 
surprising to acknowledge how much alike the two rheumatic diseases presented themselves 
in all 8 SF-36 dimensions. We are not aware of other studies comparing RA and HOA in the 
field of HRQoL as clearly. Controls and norms were similar, which supports the validity of 
the results of the chosen control population. 
5.2.3 HRQoL in patients with HOA compared to RA 
RA is considered to be a severe and disabling disease leading to impaired function and 
HRQol. In clinical practice we had observed that patients with HOA also suffered from 
considerable disability and reduced HRQoL and our study hypothesis was that HOA might 
have a similar effect on some dimensions of HRQol as RA. 
We actually showed that the global measures of HRQoL (SF-6D) were similar in patients 
with HOA and RA. However some differences were observed within other dimensions of 
HRQoL.
Functional impairment in HOA has been studied by several research groups and in different 
populations (57;116;122-124;128;223;250-252). Leeb et al showed that severity of function 
loss may be comparable in RA and OA (116). However, when a subgroup of patients being 
treated with NSAIDs in both groups were compared, RA patients showed significantly 
worse function (116). Jones et al. demonstrated a link between pain and function loss (123) 
and Bagis et al. found that structural changes on radiographs were connected to impaired 
function in HOA in postmenopausal women (122).  On the other hand, Pattrick et al. 
reported an optimistic functional development for nodal HOA compared to erosive disease 
(223).
However, none of these studies compared HRQoL in HOA with another joint disease in a 
similar, comprehensive manner involving as many questionnaires. 
Our study indicated that HOA and RA had similar impact on HRQoL, even if the primary 
objective was to focus on the comparisons with controls (Paper II). The comprehensive 
collection of data with also arthritis specific measures that were relevant both for HOA and 
RA opened the opportunity to do direct comparisons between HOA and RA (Paper III).
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Importantly, we found that patients with RA have worse physical function in several 
different scores (SF-36 physical, M-HAQ, HAQ, AIMS2) and more impaired grip strength 
for RA than patients with HOA. 
Pain is a prominent symptom in rheumatic diseases among them HOA (49) and its 
assessment is recommended (165). Yet, pain on usage can not be a specific clinical marker 
for HOA since its sensitivity is low (165). In our study pain was significantly worse in HOA 
patients in one out of three measures and numerically higher in the remaining two pain 
outcomes. Interestingly, in the study from Leeb et al. the SACRAH pain score was not 
significantly different between HOA and RA but numerically higher for HOA, which to 
some extent underlines our findings. In the subgroup of patients on NSAID treatment in the 
same Austrian study, the HOA patients showed less pain compared to RA. In retrospect, it 
might have been an advantage to perform subgroup analyses in our patients according to 
concomitant medication.  
Furthermore, both HOA and RA patients in our study showed elevated levels of FM-like 
symptoms, but the HOA patients scored numerically and partly statistically higher on 4 out 
of 5 relevant VAS indicating possible differences in pain perception beween HOA and RA. 
Clauw et al. debate that pain in rheumatic diseases might not only originate from the joint 
but also from outside the joint (253). We are not aware of previous studies exploring 
widespread pain symptoms in HOA.  
Another remarkable finding in our comparison was that mental health more impaired in 
HOA than in RA. Also this result should be further investigated and needs replication in 
other studies. 
The fact that HOA patients, even if they are not representative for the underlying general 
population, report so much pain is remarkable. The lack of effective pharmaceutical 
treatment options or access to pharmaceutical treatment might also play a role (116;117). 
Self-efficacy pain was almost identical between HOA and RA. Our longitudinal data may 
hopefully provide a chance to highlight the association between self-efficacy and HRQoL in 
HOA.
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Further, our findings may lead to a change in the appreciation of HOA as a severe disease 
and to increased awareness towards HOA in the medical community.  
5.2.4 Association between joint counts and PROs 
Assessment of joint involvement has not been part of the core measures in HOA. However, 
both joint swelling, tenderness and limited motion should have the potential to be 
responsive measures in the assessment of the condition, whereas bony enlargement, 
reflecting osteophytes, is probably not responsive. We wanted to explore both the joint
distribution and the association to outcome measures in paper IV. 
Research on distribution of joint affection in HOA has revealed that DIP joints are most 
frequently involved, followed by CMC I, PIP and MCP joints (117;122;210;216;250;254). 
It is further acknowledged that HOA is symmetrical (48;216;217;255) and that it clusters by 
row and ray (46;216;217). 
Joint involvement in the Oslo HOA cohort showed more frequently joint involvement in the 
right hand suggesting an association to the dominant hand. Involvement of DIP joints was 
most frequent, which is consistent with previous findings (210;216;250;254;256;257).
However, most of these previous studies have reported results from population based 
surveys and with joint assessment by radiographic methods or patient self-reported joint 
symptoms, and only a few studies have gained their data from smaller often hospital based 
studies (116;117;122;124). The consistency in findings regarding joint involvement across 
different methodology supports the confidence in the findings by clinical joint assessment.  
Joint counts have been infrequently applied in HOA research, so far. There is solely one 
other study by Spacek et.al. which employed joint counts in the assessment of HOA using 
the Ritchie articular index (RAI), which was developed for RA initially (124). This study 
recruited patients in a similar manner as applied in our study and further used a functional 
index the CHFS and VAS pain in the assessments, but focused on the distinction between 
nodal and thumb base HOA. Spacek et al. report that pain was associated with disability 
(124). Bagis et al. assessed tenderness by palpation, but did not execute a full joint 
examination (122). They found impaired grip and pinch strength in patients with DIP 
affection and even more so in patients with DIP and PIP involvement. Also, tenderness / 
pain lead to worse hand function. 
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Our study showed that joint tenderness/pain in the CMC, PIP and / or DIP joints was 
associated with worse health status across all measures reflecting pain, stiffness and 
physical function of the hand (AUSCAN, AIMS2 hand and finger function and VAS pain). 
Moreover, joint tenderness/pain was associated with worse function (AIMS2, SF-36 and 
HAQ and grip strength). The other three categories of abnormal joint findings were also 
correlated with worse pain and function, but not on a statistically significant level. The 
association between joint counts and outcome measures supports the external validity of 
joint counts as a potential outcome measure. 
We have later also examined the responsiveness of different combinations of joint counts as 
well as composite scores (237). The results indicated that joint counts and composite scores 
have the potential to be responsive to improvement during anti-inflammatory treatment in 
HOA. Additional research is required to try to identify valid and responsive measures taking 
joint assessments as well as patients reported measures into account. 
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6. Conclusions 
6.1 Answers to research questions 
 The background and main objective of this thesis was to examine the burden of 
disease in the Oslo HOA cohort. We have been able to show that the AUSCAN 
performs well in the Norwegian translation and is valid and reliable.
 Further the thesis showed that HOA and RA patients had worse health and a 
substantial burden of disease compared to controls and population norms.  
 RA patients experienced a higher level of disability and functional impairment than 
HOA patients. The HOA patients reported higher levels of pain and FM-like 
symptoms than the RA group.  
 DIP joints were most frequently affected in the Oslo HOA cohort and the joint 
assessment for pain was correlated to impaired health to a greater degree than the 
other joint assessments. 
 In summary, the burden of disease is considerable in HOA despite being generally 
perceived as a mild rheumatic disease.  
6.2 Clinical implications 
We have in this study demonstrated that HOA is a disease which leads to considerable pain, 
disability and impaired HRQoL. Importantly, we have also shown that the overall decrease 
in HRQoL is close to the level of patients with RA. Hopefully, these findings may 
contribute to a raised awareness for HOA as a disease that requires increased attention from 
society, patients, researchers and clinicians. Unfortunately effective treatment modalities are 
still limited. Effective disease modifying therapies will hopefully be available in the future. 
Assessment of therapies requires availability of reliable, valid and responsive outcome 
measures. Parts of this thesis have hopefully contributed to progress in the identification of 
such measures. 
This thesis is based on cross sectional data. However, the plan has always been to conduct a 
follow up examination of these patients, since long-term data are more valuable for the 
prediction of the course of the disease and outcomes. The follow up examination has been 
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performed in 2008 / 2009 with stronger focus on imaging modalities than in the cross-
sectional data. The initial cross-sectional research was the basis for the longitudinal follow 
up of patients with HOA in our clinic and has contributed to an increased research interest 
for HOA. The research focus also stimulated the initiation of the OA clinic in 2003 which 
has provided a novel, dedicated and multidisciplinary management opportunity for patients 
with OA in the clinical setting (258). 
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7. Errata 
Article III 
Page 344, HAQ and MHAQ – the explanation, the arthritis impact measurement scale 2 - is 
incorrect, the correct definition is health assessment questionnaire and modified health 
assessment questionnaire. 
Article IV 
Page 3, discussion, paragraph 4, DIP and DIP joints is incorrect – the correct terms are DIP 
and PIP joints. 
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